Prospectus Supplement Adds New Selling Stockholders for 400,000 Warrant Shares Resale

summarizeSummary

Protara Therapeutics filed a prospectus supplement to include new selling stockholders, Warberg Special Situations Fund LP and Warberg WF XIII LP, who may resell up to 400,000 shares underlying warrants.

check_boxKey Events

• New Selling Stockholders Added

  Warberg Special Situations Fund LP and Warberg WF XIII LP have been added as selling stockholders via an assignment of common warrants.

• Potential Resale of 400,000 Shares

  These new selling stockholders may resell up to 400,000 shares of common stock underlying warrants.

• No Proceeds to Company

  The company will not receive any proceeds from the sale of shares by these selling stockholders.

• Follows Recent Institutional Selling

  This update comes amidst a series of Form 144 filings from other institutional investors (Baker Brothers) indicating intent to sell shares.

auto_awesomeAnalysis

This 424B7 filing updates a previous resale prospectus, adding Warberg Special Situations Fund LP and Warberg WF XIII LP as new selling stockholders. These entities received an assignment of common warrants exercisable for a total of 400,000 shares. While the company receives no proceeds from these potential sales, the addition of new institutional investors intending to resell shares contributes to an overhang on the stock. This follows a series of Form 144 filings from other institutional investors (Baker Brothers) in recent days, indicating a broader trend of institutional selling pressure.